
Novartis’ Intrathecal Zolgensma Effective in Older Children
Six years ago, the FDA approved Novartis’ Zolgensma as the first gene therapy for children under two years of age with spinal muscular atrophy. Wednesday, the company reported late-stage data from an intrathecal form of the gene therapy that appears to be …